We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$627M
AUM Growth
-$205M
Cap. Flow
-$88.2M
Cap. Flow %
-14.06%
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.4M
2
HUM icon
Humana
HUM
+$14.8M
3
PFE icon
Pfizer
PFE
+$14.2M
4
MCK icon
McKesson
MCK
+$11M
5
AMGN icon
Amgen
AMGN
+$10.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$18.6M
3
UNH icon
UnitedHealth
UNH
+$10.1M
4
RAD
Rite Aid Corporation
RAD
+$9.6M
5
CVS icon
CVS Health
CVS
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.99%
2 Financials 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
26
Community Health Systems
CYH
$423M
$9.41M 1.5%
266,200
+133,100
+100% +$6.1M
CVS icon
27
CVS Health
CVS
$122B
$9.36M 1.49%
97,000
-87,000
-47% -$9.15M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$12.4B
$9.06M 1.44%
86,000
-6,000
-7% -$801K
HNT
29
DELISTED
HEALTH NET INC
HNT
$9.03M 1.44%
+150,000
New +$9.94M
EW icon
30
Edwards Lifesciences
EW
$51.7B
$8.81M 1.41%
372,000
+204,000
+121% +$4.92M
LH icon
31
Labcorp
LH
$25.9B
$8.79M 1.4%
94,284
+12,804
+16% +$1.32M
CEMP
32
DELISTED
Cempra, Inc.
CEMP
$8.3M 1.32%
298,000
+20,839
+8% +$774K
ESRX
33
DELISTED
Express Scripts Holding Company
ESRX
$7.77M 1.24%
96,000
+17,000
+22% +$1.48M
REGN icon
34
Regeneron Pharmaceuticals
REGN
$80.8B
$7.67M 1.22%
16,500
-2,500
-13% -$1.34M
NKTR icon
35
Nektar Therapeutics
NKTR
$2.58B
$7.54M 1.2%
45,867
-16,600
-27% -$2.94M
DXCM icon
36
DexCom
DXCM
$32B
$7.21M 1.15%
336,000
-32,000
-9% -$714K
ABMD
37
DELISTED
Abiomed Inc
ABMD
$7.05M 1.12%
76,000
-28,000
-27% -$2.47M
CERN
38
DELISTED
Cerner Corp
CERN
$6.96M 1.11%
116,000
+33,000
+40% +$2.16M
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.61M 1.05%
165,000
-41,000
-20% -$1.34M
ZBH icon
40
Zimmer Biomet
ZBH
$18.4B
$6.58M 1.05%
+72,100
New +$7.23M
ACAD icon
41
Acadia Pharmaceuticals
ACAD
$5.03B
$6.48M 1.03%
196,000
+5,000
+3% +$208K
JAZZ icon
42
Jazz Pharmaceuticals
JAZZ
$16.7B
$6.2M 0.99%
46,700
-23,300
-33% -$4.01M
ALNY icon
43
Alnylam Pharmaceuticals
ALNY
$29.3B
$6.11M 0.97%
76,000
+14,600
+24% +$1.62M
UHS icon
44
Universal Health Services
UHS
$10.5B
$6.1M 0.97%
48,900
-16,100
-25% -$2.24M
COR icon
45
Cencora
COR
$61.2B
$5.98M 0.95%
63,000
+21,000
+50% +$2.2M
KERX
46
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$5.5M 0.88%
1,563,000
+1,029,000
+193% +$6.89M
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.31M 0.85%
32,000
+8,000
+33% +$1.76M
ENDP
48
DELISTED
Endo International plc
ENDP
$5.06M 0.81%
73,000
+14,024
+24% +$1.12M
ZLTQ
49
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$5.03M 0.8%
157,000
+28,000
+22% +$927K
SUPN icon
50
Supernus Pharmaceuticals
SUPN
$2.77B
$4.96M 0.79%
353,328
-63,672
-15% -$1.18M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rhenman & Partners Asset Management held 102 positions worth $627M, down 25% from $833M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $88.2M in Q3 2015, closing 11 positions and reducing 34 holdings. Its most notable exit was Biogen, an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 77% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cigna worth $14.3M.

  • Rhenman & Partners Asset Management's largest Q3 2015 buy was Cigna: 105,900 shares worth $14.3M.
  • Rhenman & Partners Asset Management added most to McKesson in Q3 2015, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2015 reduction was UnitedHealth, cutting an estimated $10.1M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q3 2015, selling an estimated $20.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $627M portfolio in Q3 2015.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 11 in Q3 2015.
  • Rhenman & Partners Asset Management's portfolio value fell 25% quarter-over-quarter to $627M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2015, filed 26 Oct 2015.